DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



A Study of Axiron® in Healthy Participants

Information source: Eli Lilly and Company
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Healthy Volunteers

Intervention: Axiron (Drug)

Phase: Phase 1

Status: Completed

Sponsored by: Eli Lilly and Company

Official(s) and/or principal investigator(s):
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), Study Director, Affiliation: Eli Lilly and Company

Summary

The study involves application of Axiron to each underarm. The study will evaluate the transfer of testosterone from underarms to the clothing items that the participant is wearing and other fabric items washed with participant's' clothes. The study is approximately 6 days, not including screening. Screening is required within 28 days prior to the start of the study.

Clinical Details

Official title: A Phase 1, Single-Dose Study to Evaluate Testosterone on Clothing After Axiron Use in Healthy Male Subjects

Study design: Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science

Primary outcome: Amount of Testosterone on T-shirts

Secondary outcome:

Amount of Testosterone Following Laundering

Amount of Testosterone on Unworn Textiles Laundered With the Testosterone Exposed T-shirts

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Male.

Criteria:

Inclusion Criteria:

- Are overtly healthy males, as determined by medical history and physical examination,

or males who have been on stable medication for at least 1 month and have no significant clinical conditions.

- Agree to use a reliable method of birth control (for example: condom or vasectomy)

during the study and for 3 months following the Axiron dose

- Have clinical laboratory test results within the normal reference range for the

population or investigator site, or results with acceptable deviations that are judged to be not clinically significant by the investigator

- Are reliable and willing to make themselves available for the duration of the study

and are willing to follow study procedures

- Have given written informed consent approved by Lilly and the ethical review board

(ERB) governing the site Exclusion Criteria:

- Are currently enrolled in a clinical trial involving an investigational product or

off-label use of a drug or device, or are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study

- Are participants who have previously completed or withdrawn from this study or any

other study investigating Axiron in the past 3 months

- Have known allergies to testosterone solution, related compounds, or any components

of the formulation, or history of significant atopy

- Have an abnormality in the 12-lead electrocardiogram (ECG) that, in the opinion of

the investigator, increases the risks associated with participating in the study

- Have an abnormal blood pressure as determined by the investigator

- Have a history of or current cardiovascular, respiratory, hepatic, renal,

gastrointestinal, endocrine, hematological, or neurological disorders constituting a risk when taking the study medication or that could interfere with the interpretation of the data

- Have had lymphoma, leukemia, or any malignancy within the past 5 years except for

basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of metastatic disease for 3 years

- Regularly use known drugs of abuse and/or show positive findings on urinary drug

screening

- Show evidence of human immunodeficiency virus (HIV) infection and/or positive human

HIV antibodies

- Show evidence of hepatitis C and/or positive hepatitis C antibody

- Show evidence of hepatitis B and/or positive hepatitis B surface antigen

- Use of any topical testosterone replacement therapy within the 3 months prior to

study entry through study discharge, except for use of Axiron as directed by study procedures

- Use of parenteral testosterone replacement (testosterone enthanate, testosterone

cypionate) within the 30 days prior to screening. Use of long acting intramuscular testosterone undecanoate 6 months prior to screening, or use of testosterone pellets 12 months prior to screening

- Have a dermatologic condition in the underarm area that might be exacerbated by

topical testosterone replacement therapy, in the opinion of the investigator

- In the opinion of the investigator or sponsor, are unsuitable for inclusion in the

study

Locations and Contacts

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Daytona Beach, Florida, United States
Additional Information

Starting date: December 2013
Last updated: July 29, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017